New Horizons for Clinical Treatment
Parts 1 & 2
For millennia, cultures around the world have embraced mind-altering substances to catalyze healing. Although our field has generally resisted the use of such substances, the FDA has recently granted “breakthrough therapy” designation to MDMA-assisted psychotherapy as it enters the final stage of clinical trials. There’s increasing buzz about the potential of MDMA, also known as Ecstasy, to treat an array of issues, including trauma, anxiety, depression, relationship blocks, and even drug addiction. With continued FDA support, certified MDMA-assisted therapists could be practicing very soon. In this workshop, you’ll explore:
- Cutting-edge research on MDMA-assisted psychotherapy for PTSD, and how this drug can help catalyze healing and clear away treatment obstacles
- The role therapists must play in the eight-hour MDMA sessions, and how to facilitate the important talk-therapy sessions that precede and follow it
- Current and future opportunities for practicing MDMA-assisted psychotherapy, and what it might take to integrate this work into your work
Continued with workshop 308
Michael Mithoefer, MD, is a psychiatrist in Charleston, SC. He specializes in experiential methods of psychotherapy to treat PTSD, and conducted the first FDA-approved clinical trials of MDMA-assisted psychotherapy for PTSD. He now trains and supervises therapists involved in the final phase of the trials.